Abstract：
BACKGROUND: The augmentative antidepressant effects of dopamine partial agonists (aripiprazole, brexpiprazole, and cariprazine) for treatment-resistant depression have been compared in a previous network meta-analysis. However, the comparative efficacy of the dose-responses of these drugs remains unclear. Therefore, we aimed to estimate the dose-response relationships and compare the effects of each dopamine partial agonist doses.
METHODS: We conducted a systematic review of the Cochrane Library, PubMed, CINHAL, and ClinicalTrials.gov databases until January 1, 2023. Double-blind, randomized, placebo-controlled trials evaluating aripiprazole, brexpiprazole, and cariprazine for treatment-resistant depression were included. A random-effect dose-response model-based network meta-analysis was conducted. This study was registered in PROSPERO (CRD42023393035).
RESULTS: The maximum effective doses were 5.5 mg for aripiprazole, 1.6 mg for brexpiprazole, and 1.5 mg for cariprazine, respectively. Although all doses of the 3 drugs were significantly more effective than placebo, aripiprazole ranging from 5.5 to 12.5 mg was significantly more effective than brexpiprazole 0.5 mg and cariprazine ranging from 0.5 to 1 mg. Moreover, aripiprazole ranging from 7.5 to 12.5 mg was significantly more effective than all doses of cariprazine. In addition, brexpiprazole ranging from 1 to 3 mg was significantly more effective than cariprazine 0.5 mg and brexpiprazole ranging from 1.6 to 2.5 mg was significantly superior to cariprazine 1 mg. There were no doses at which brexpiprazole overcame aripiprazole, and cariprazine overcame aripiprazole or brexpiprazole.
CONCLUSIONS: Aripiprazole, brexpiprazole, and cariprazine may be effective in treatment-resistant depression in that order, with the maximum effective doses at 5.5 mg, 1.6 mg, and 1.5 mg, respectively.
METHODS: We conducted a systematic review of the Cochrane Library, PubMed, CINHAL, and ClinicalTrials.gov databases until January 1, 2023. Double-blind, randomized, placebo-controlled trials evaluating aripiprazole, brexpiprazole, and cariprazine for treatment-resistant depression were included. A random-effect dose-response model-based network meta-analysis was conducted. This study was registered in PROSPERO (CRD42023393035).
RESULTS: The maximum effective doses were 5.5 mg for aripiprazole, 1.6 mg for brexpiprazole, and 1.5 mg for cariprazine, respectively. Although all doses of the 3 drugs were significantly more effective than placebo, aripiprazole ranging from 5.5 to 12.5 mg was significantly more effective than brexpiprazole 0.5 mg and cariprazine ranging from 0.5 to 1 mg. Moreover, aripiprazole ranging from 7.5 to 12.5 mg was significantly more effective than all doses of cariprazine. In addition, brexpiprazole ranging from 1 to 3 mg was significantly more effective than cariprazine 0.5 mg and brexpiprazole ranging from 1.6 to 2.5 mg was significantly superior to cariprazine 1 mg. There were no doses at which brexpiprazole overcame aripiprazole, and cariprazine overcame aripiprazole or brexpiprazole.
CONCLUSIONS: Aripiprazole, brexpiprazole, and cariprazine may be effective in treatment-resistant depression in that order, with the maximum effective doses at 5.5 mg, 1.6 mg, and 1.5 mg, respectively.
摘要：
背景：多巴胺部分激动剂的增强抗抑郁作用（阿立哌唑，布立哌唑,和卡利拉嗪）在先前的网络荟萃分析中对难治性抑郁症进行了比较。然而,这些药物的剂量反应的比较疗效仍不清楚.因此,我们旨在评估剂量-反应关系,并比较每种多巴胺部分激动剂剂量的作用.
方法：我们对Cochrane图书馆进行了系统评价，PubMed,CINHAL,和ClinicalTrials.gov数据库，直到2023年1月1日。双盲,随机化，安慰剂对照试验评估阿立哌唑，布立哌唑,包括卡利拉嗪治疗难治性抑郁症。进行了基于随机效应剂量反应模型的网络荟萃分析。本研究在PROSPERO（CRD42023393035）注册。
结果：阿立哌唑的最大有效剂量为5.5mg，1.6毫克用于布列哌唑，卡利拉嗪1.5毫克，分别。尽管3种药物的所有剂量都比安慰剂有效，5.5~12.5mg的阿立哌唑比0.5mg和0.5~1mg的卡利拉嗪更有效.此外，7.5~12.5mg的阿立哌唑比所有剂量的卡利拉嗪更有效.此外,1~3mg的巴立哌唑明显优于0.5mg的卡利拉嗪,1.6~2.5mg的巴立哌唑明显优于1mg的卡利拉嗪.没有任何剂量的巴立哌唑可以战胜阿立哌唑，卡利拉嗪战胜了阿立哌唑或布立哌唑。
结论：阿立哌唑，布立哌唑,卡利拉嗪可能对治疗难治性抑郁症有效，最大有效剂量为5.5毫克，1.6mg,和1.5毫克，分别。
方法：我们对Cochrane图书馆进行了系统评价，PubMed,CINHAL,和ClinicalTrials.gov数据库，直到2023年1月1日。双盲,随机化，安慰剂对照试验评估阿立哌唑，布立哌唑,包括卡利拉嗪治疗难治性抑郁症。进行了基于随机效应剂量反应模型的网络荟萃分析。本研究在PROSPERO（CRD42023393035）注册。
结果：阿立哌唑的最大有效剂量为5.5mg，1.6毫克用于布列哌唑，卡利拉嗪1.5毫克，分别。尽管3种药物的所有剂量都比安慰剂有效，5.5~12.5mg的阿立哌唑比0.5mg和0.5~1mg的卡利拉嗪更有效.此外，7.5~12.5mg的阿立哌唑比所有剂量的卡利拉嗪更有效.此外,1~3mg的巴立哌唑明显优于0.5mg的卡利拉嗪,1.6~2.5mg的巴立哌唑明显优于1mg的卡利拉嗪.没有任何剂量的巴立哌唑可以战胜阿立哌唑，卡利拉嗪战胜了阿立哌唑或布立哌唑。
结论：阿立哌唑，布立哌唑,卡利拉嗪可能对治疗难治性抑郁症有效，最大有效剂量为5.5毫克，1.6mg,和1.5毫克，分别。
